A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

[1]  B. Choudhary,et al.  Triple-negative breast cancer: A run-through of features, classification and current therapies , 2021, Oncology letters.

[2]  G. Simone,et al.  Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role , 2020, Frontiers in Cell and Developmental Biology.

[3]  J. Lemonnier,et al.  VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study , 2020, Pharmaceuticals.

[4]  Paul Vare,et al.  The beginning of the end, or the end of the beginning? , 2020 .

[5]  L. Pusztai,et al.  Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. , 2020, Journal of the National Cancer Institute.

[6]  Bevacizumab , 2019, Reactions Weekly.

[7]  A. Giordano,et al.  Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. , 2019, The Lancet. Oncology.

[8]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[9]  Xinghuan Wang,et al.  The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function , 2016, Medicine.

[10]  R. Danesi,et al.  Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. , 2014, Pharmacogenomics.

[11]  M. Ritchie,et al.  Genomic analyses with biofilter 2.0: knowledge driven filtering, annotation, and model development , 2013, BioData Mining.

[12]  P. Carmeliet,et al.  Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Miles,et al.  Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer , 2013, British Journal of Cancer.

[14]  Ting Hu,et al.  Epistasis, complexity, and multifactor dimensionality reduction. , 2013, Methods in molecular biology.

[15]  P. Hegde,et al.  Predictive Impact of Circulating Vascular Endothelial Growth Factor in 4 Phase Iii Trials Evaluating Bevacizumab Departments of 1 , 2022 .

[16]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Ellis,et al.  Antiangiogenic therapy—evolving view based on clinical trial results , 2012, Nature Reviews Clinical Oncology.

[18]  H. Rugo,et al.  Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Jayson,et al.  803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC) , 2011 .

[20]  G. Bocci,et al.  Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. , 2011, Pharmacogenomics.

[21]  M. Espié,et al.  Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. , 2011, British journal of clinical pharmacology.

[22]  C. Punt,et al.  Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Catalano,et al.  Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer , 2011, BMC Cancer.

[25]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Gray,et al.  A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). , 2010 .

[27]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[28]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[30]  Todd Holden,et al.  A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. , 2006, Journal of theoretical biology.

[31]  Jason H. Moore,et al.  Ideal discrimination of discrete clinical endpoints using multilocus genotypes , 2004, Silico Biol..

[32]  D. Ray,et al.  Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. , 2003, Cancer research.